C4 Therapeutics, Inc.
CCCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11,230 | $6,463 | $7,238 | $5,177 |
| % Growth | 73.8% | -10.7% | 39.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1,766 |
| Gross Profit | $11,230 | $6,463 | $7,238 | $3,411 |
| % Margin | 100% | 100% | 100% | 65.9% |
| R&D Expenses | $25,989 | $26,197 | $27,072 | $32,513 |
| G&A Expenses | $8,920 | $8,767 | $9,330 | $10,373 |
| SG&A Expenses | $8,920 | $8,767 | $9,330 | $10,373 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $10,733 | $0 | $0 | -$1,766 |
| Operating Expenses | $45,642 | $34,964 | $36,402 | $41,120 |
| Operating Income | -$34,412 | -$28,501 | -$29,164 | -$37,709 |
| % Margin | -306.4% | -441% | -402.9% | -728.4% |
| Other Income/Exp. Net | $2,246 | $2,481 | $2,842 | $3,267 |
| Pre-Tax Income | -$32,166 | -$26,020 | -$26,322 | -$34,442 |
| Tax Expense | $0 | $0 | $0 | $131 |
| Net Income | -$32,166 | -$26,020 | -$26,322 | -$34,573 |
| % Margin | -286.4% | -402.6% | -363.7% | -667.8% |
| EPS | -0.44 | -0.37 | -0.37 | -0.49 |
| % Growth | -18.9% | 0% | 24.5% | – |
| EPS Diluted | -0.44 | -0.37 | -0.37 | -0.49 |
| Weighted Avg Shares Out | 72,563 | 71,006 | 70,833 | 70,606 |
| Weighted Avg Shares Out Dil | 72,563 | 71,006 | 70,833 | 70,606 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,246 | $2,481 | $2,842 | $3,267 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $460 | $615 | $456 | $1,766 |
| EBITDA | -$31,706 | -$27,886 | -$28,708 | -$32,676 |
| % Margin | -282.3% | -431.5% | -396.6% | -631.2% |